semaglutide 7.2 mg clinical trial Once-weekly 7·2 in adults with obesity (STEP UP): a randomised, controlled, phase 3b European Commission Approves 7.2 mg – How do I use the

As semaglutide generics expand beyond India into markets such as Brazil, Canada, and China, the patterns observed in India rapid price erosion and strong reliance on China for API and KSM manufacturing are likely to repeat

These cities aim to become more resilient, inclusive, and environmentally conscious by reconfiguring their systems, structures, and governance

These changes directly reduce the raw materials that contribute to atherosclerotic plaque formation

The FDA has approved Wegovy (semaglutide) and Zepbound (tirzepatide) specifically for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia